Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis

Andrew Kuykendall, Francesca Palandri, Bella Vo, Fulya Sen Nikitas, Nicholas Meader, Shiyuan Zhang, Tom (sizhu) Liu, Shuang Wang, Gautam Sajeev, Mirko Fillbrunn, James Signorovitch, Jasmine Sahni, Dwaipayan Patnaik, Aaron Gerds

Blood (2025) 146 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2025-2031

Published: 2025

Journal Articles

Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY-1 trial

Stephen Oh, Juan Carlos Hernandez Boluda, Jean-Jacques Kiladjian, Viviane Dubruille, Christian Recher, Alexandre Lockhart, Chandan Kumar, Hanny Musa, Jasmine Sahni, Dwaipayan Patnaik, Claire Harrison

Blood (2025) 146 (Supplement 1): 2025.

https://doi.org/10.1182/blood-2025-2025

Published: 2025

Journal Articles

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM

Francesca Palandri, Nicolaas Schaap, Jérôme Rey, Nikolas Von Bubnoff, Andreas Reiter, Juan Carlos Hernandez Boluda, Timothy Devos, Bethan Psaila, Donal McLornan, Catherine Ellis, Fulya Sen Nikitas, Shiyuan Zhang, Jessica Lim, Dwaipayan Patnaik, Stephen Oh

Blood (2025) 146 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2025-2023

Published: 2025

Journal Articles

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Vikas Gupta, Francesca Palandri, Jean-Jacques Kiladjian, Bethan Psaila, Bella Vo, Jessica Lim, Fulya Sen Nikitas, Shiyuan Zhang, Tom (sizhu) Liu, Catherine Ellis, Jasmine Sahni, Dwaipayan Patnaik, Stephen Oh, Ruben Mesa

Blood (2025) 146 (Supplement 1): 3809.

https://doi.org/10.1182/blood-2025-3809

Published: 2025

Journal Articles

Preliminary experience from the ODYSSEY trial: Efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis

Prithviraj Bose, Jean-Christophe Ianotto, Regina Garcia-Delgado, Jonathan Abbas, Jasmine Sahni, Dwaipayan Patnaik, Catherine Ellis, Sunny Kim, Vikas Gupta

Blood (2025) 146 (Supplement 1): 3803.

https://doi.org/10.1182/blood-2025-3803

Published: 2025

Journal Articles

Discovery of drug combinations with momelotinib to improve myelofibrosis outcomes

Shane O'Brien, Shannon McKearnan, Ashley Lento, Jeffrey Guss, Anna Waszkiewicz, Bin Wu, Allison Hartman, Matthew Powell, Gabriella Cifelli, Maggie Connelly, Sungtae Kim, Hoang Tran, Dwaipayan Patnaik, Mary Antonysamy, Michael McCabe, Anthony Mazurek

Blood (2025) 146 (Supplement 1): 7279.

https://doi.org/10.1182/blood-2025-7279

Published: 2025

Journal Articles

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials

Francesca Palandri, Casey O'Connell, Pankit Vachhani, Donal McLornan, Steffen Koschmieder, Juan Carlos Hernandez Boluda, Catherine Ellis, Tom (sizhu) Liu, Shiyuan Zhang, Jessica Lim, Dwaipayan Patnaik, Vikas Gupta

Blood (2025) 146 (Supplement 1): 5581.

https://doi.org/10.1182/blood-2025-5581

Published: 2025

Journal Articles

Association between momelotinib exposure and hemoglobin improvement in patients with myelofibrosis and anemia: An exposure-response and time-to-event analysis

Vikas Gupta, Jose Torregrosa, Georgios Vlasakakis, Meenakshi Srinivasan, Fernando Carreño, Jasmine Sahni, Dwaipayan Patnaik, Kazuya Shimoda

Blood (2025) 146 (Supplement 1): 5580.

https://doi.org/10.1182/blood-2025-5580

Published: 2025

Journal Articles

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

Raajit Rampal, Prithviraj Bose, Vikas Gupta, Francesca Palandri, Shiyuan Zhang, Jessica Lim, Fulya Sen Nikitas, Tom (sizhu) Liu, Jasmine Sahni, Catherine Ellis, Dwaipayan Patnaik, Florian Heidel, Francesco Passamonti

Blood (2025) 146 (Supplement 1): 5579.

https://doi.org/10.1182/blood-2025-5579

Published: 2025

Journal Articles

Momelotinib's unique polypharmacology supports indication expansion beyond myelofibrosis

Shane O'Brien, Henrik Hammarén, Bryan Strouse, Mary Antonysamy, Dwaipayan Patnaik, Hoang Tran, Anthony Mazurek, Michael McCabe

Blood (2025) 146 (Supplement 1): 7853.

https://doi.org/10.1182/blood-2025-7853

Published: 2025

Journal Articles

Enhanced antileukemic activity of momelotinib in combination with venetoclax and azacitidine compared to gilteritinib-based combination

Zachary Kincaid, Sekhu Ansari, Joshua Schwieterman, Mary Antonysamy, Dwaipayan Patnaik, Shane O'Brien, Michael McCabe, Mohammad Azam

Blood (2025) 146 (Supplement 1): 7850.

https://doi.org/10.1182/blood-2025-7850

Published: 2025

Journal Articles

Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States

Andrew T. Kuykendall, Francesca Palandri, Shiyuan Zhang, Tom Liu, Mirko Fillbrunn, Adina Zhang, Gautam Sajeev, James Signorovitch, Dwaipayan Patnaik, Aaron T. Gerds

Blood (2024) 144 (Supplement 1): 3804.

https://doi.org/10.1182/blood-2024-205380

Published: 2024

Journal Articles

Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison

Francesca Palandri, Venediktos Kapetanakis, Balazs Dobi, Filippo Branzanti, Catherine Ellis, Nick Ballew, Tom Liu, Kelesitse Phiri, Fulya Sen Nikitas, Melania Biasi, Shiyuan Zhang, Dwaipayan Patnaik

Blood (2024) 144 (Supplement 1): 3187.

https://doi.org/10.1182/blood-2024-205973

Published: 2024

Journal Articles

Experienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self-Report Survey Analysis

Thomas W. LeBlanc, Hannah Collacott, Valentín García Gutiérrez, Sr., Ned Weinshenker, Ruth Fein Revell, Alicia O'Neill, Anna P Cardellino, Shiyuan Zhang, Dwaipayan Patnaik, Melissa Ross

Blood (2024) 144 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2024-206086

Published: 2024

Journal Articles

Time without Transfusion Reliance or Anemia Worsening: A Novel Method for Integrating Transfusion Dependence, Anemia, and Survival with Myelofibrosis Therapies Based on the Phase 3 Simplify-1 and Simplify-2 Trials

Ruben A. Mesa, Moshe Talpaz, Flora Mazerolle, Boris Gorsh, Manal M'Hari, Antoine Regnault, Catherine Ellis, Zhaohui Wang, Molly Purser, Tom Liu, Bryan Strouse, Dwaipayan Patnaik

Blood (2023) 142 (Supplement 1): 1826.

https://doi.org/10.1182/blood-2023-177784

Published: 2023

Journal Articles

Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials

Vikas Gupta, Claire N Harrison, Boris Gorsh, Bharat Patel, Zhaohui Wang, Molly Purser, Catherine Ellis, Bryan Strouse, Dwaipayan Patnaik, Jun Kawashima, Ruben A. Mesa

Blood (2023) 142 (Supplement 1): 3188.

https://doi.org/10.1182/blood-2023-178772

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis

Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY-1 trial

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Preliminary experience from the ODYSSEY trial: Efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis

Discovery of drug combinations with momelotinib to improve myelofibrosis outcomes

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials

Association between momelotinib exposure and hemoglobin improvement in patients with myelofibrosis and anemia: An exposure-response and time-to-event analysis

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

Momelotinib's unique polypharmacology supports indication expansion beyond myelofibrosis

Enhanced antileukemic activity of momelotinib in combination with venetoclax and azacitidine compared to gilteritinib-based combination

Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States

Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison

Experienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self-Report Survey Analysis

Time without Transfusion Reliance or Anemia Worsening: A Novel Method for Integrating Transfusion Dependence, Anemia, and Survival with Myelofibrosis Therapies Based on the Phase 3 Simplify-1 and Simplify-2 Trials

Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only